1. What is TB-500?
TB-500 is the synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring peptide found in nearly all human and animal cells. Tβ4 has been investigated for its role in cell migration, tissue remodeling, angiogenesis, and inflammation modulation. TB-500 has been developed to explore these properties in a research context, providing a stable and bioavailable model peptide for scientific studies.
2. TB-500 Structure
Molecular Formula： C₃₈H₆₈N₁₀O₁₄
Molecular Weight：889.0g/mol
CAS Number：77591-33-4
3. TB-500 Research
【1】Molecular Mechanisms
l Actin modulation: TB-500 interacts with G-actin, regulating polymerization and supporting cell migration processes.
l Angiogenesis: Encourages endothelial movement and vessel formation, aiding oxygen and nutrient delivery.
l Inflammatory modulation: Shown to suppress pro-inflammatory cytokines and mobilize progenitor cells, potentially reducing fibrosis 【1】.
l Extracellular matrix remodeling: Supports collagen deposition and scar-tissue regulation 【2】.
l Multi-tissue evidence: Animal models suggest roles in dermal, cardiac, corneal, and neural repair 【3】.
【2】Preclinical & Early Evidence
l Rodent wound healing: Improved re-epithelialization and scar quality 【4】.
l Diabetic wound models: Enhanced healing rates via collagen remodeling 【5】.
l Corneal and dermal repair: Accelerated closure and reduced apoptosis in ocular models 【6】.
l Neurological recovery: Studies in rodents suggest vascular and oligodendrocyte activation in ischemic models.
✅ Why Consider TB-500 ?
l Broad regenerative scope: Explored for activity in skin, soft tissue, cardiac, and neural repair.
l Anti-fibrotic potential: Associated with improved quality of tissue remodeling.
l Synergistic research use: Often paired with other peptides (e.g., BPC-157) in experimental studies.
l Angiogenesis & cell migration: Provides a model for understanding vascular growth and cellular mobility.
l Preclinical support: Multiple animal studies highlight consistent outcomes across tissue types.
4. Future TB-500 Research
l Human clinical trials: Required to validate animal findings in wound care, cardiovascular recovery, and ocular health.
l Mechanistic studies: Transcriptomic and biomarker profiling of angiogenesis, inflammation, and regeneration pathways.
l Innovative delivery systems: Hydrogels, microneedles, and sustained-release formulations under investigation.
l Comparative efficacy: Evaluation alongside BPC-157 or other regenerative peptides.
l Organ-specific exploration: Ongoing interest in cardiac, diabetic wound, corneal, and CNS applications.
5. Application Areas
|
Scenario
|
TB-500 Contribution (Research)
|
|
Skin & Wound Healing
|
Studied for re-epithelialization and scar modulation
|
|
Muscle & Tendon Support
|
Investigated for collagen regulation and mobility
|
|
Ulcer & Diabetic Models
|
Preclinical data show enhanced wound closure
|
|
Post-Surgical Recovery
|
Explored for graft integration and scar quality
|
|
Cardiac Models
|
Studied for vascular repair in myocardial ischemia
|
|
Corneal Repair
|
Evidence of reduced apoptosis and faster closure
|
|
Neurological Studies
|
Suggested roles in vascular and glial activation
|
|
Sports Recovery Research
|
Examined in performance-related recovery models
|
✅ Summary
TB-500 is a synthetic research peptide modeled on thymosin beta-4, widely studied for its role in cell migration, angiogenesis, and tissue repair. Preclinical data highlight potential benefits across wound healing, cardiac recovery, ocular models, and neuroregeneration. While promising, further controlled human trials are necessary to confirm its translational potential.
⚠ Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
